Radiotherapy Treatments for Neoplasms in the Abdominal-pelvic Region

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective and safe radiotherapy (a type of cancer treatment using high-energy rays) is for patients with cancers located in the abdominal and pelvic areas. This includes cancers of the stomach, intestines, reproductive organs, urinary system, and other nearby structures. The trial aims to evaluate the treatment's effectiveness and how well patients tolerate it, whether they are receiving it to try to cure their cancer or to relieve symptoms.

To participate in the trial, patients should be aged 65 to 74 and should have had radiotherapy for various types of cancers in the abdominal-pelvic region. Participants will need to sign a consent form to confirm they understand the trial and agree to take part. If you or a loved one is considering joining this study, you can expect to receive specialized care while contributing to important research that may help improve future cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the abdominal-pelvic region for:
• • Primary tumors of the gastrointestinal tract, Primary tumors of the male and female reproductive systems, Primary tumors of the urinary system, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system, Skin tumors, Secondary abdominal-pelvic localizations of various origins, Primary or secondary bone or soft tissue lesions of the lumbosacral spine and pelvis.
• • 2. Signed informed consent
• Exclusion Criteria:
• • 1. Radiotherapy in districts other than the abdominal-pelvic region